Tranilast

Tranilast

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	none
Legal status
Legal status	US: Not FDA approved In general: ℞ (Prescription only)
Identifiers
IUPAC name 2-{[(2E)-3-(3,4-Dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid
CAS Number	53902-12-8
PubChem CID	5282230
IUPHAR/BPS	6326
ChemSpider	4445411
UNII	HVF50SMY6E
ChEBI	CHEBI:77572
ChEMBL	ChEMBL415324
CompTox Dashboard (EPA)	DTXSID7023693
ECHA InfoCard	100.150.125
Chemical and physical data
Formula	C18H17NO5
Molar mass	327.336 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=C(C=C(C=C1)C=CC(=O)NC2=CC=CC=C2C(=O)O)OC
InChI InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+ Key:NZHGWWWHIYHZNX-CSKARUKUSA-N

Tranilast (INN, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in the 1980s.